A Gene Targeting Therapy for Angelman Syndrome Failed Its Final Trial, Leaving Families Without an Approved Option

Ultragenyx says apazunersen missed both endpoints in the Phase 3 Aspire trial for Angelman syndrome, and no approved therapy exists.

Have A Referral?